The Cancer Center Amsterdam (CCA) has just received the much anticipated Illumina MiSeq Personal Sequencing System. Generous support of CCA-V/ICI has allowed the Department of Pathology to acquire this state of the art Massively Parallel Sequencing (MPS) technology, which was developed specifically for clinical diagnostic applications. The simple and robust work flow, high quality data and fast turnover rates, will allow us to rapidly bring this new technology into the clinic and to the benefit of patients at VUmc.
The MiSeq will revolutionize molecular diagnostics and is pivotal in patient tailored medicine. This is achieved since not one or several genes are sequenced but hundreds of genes simultaneously in only several hours. The complete molecular picture that is obtained of the patient samples will allow a rapid and comprehensive diagnosis.